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OBJECTIVE: To calculate incremental cost-utility ratios for an
additional 12-weeks varenicline treatment as compared to the
initial 12 weeks (successful) varenicline treatment for a 50-year
follow-up period. METHODS: The Beneﬁts of Smoking Cessa-
tion on Outcomes (BENESCO) model was used to simulate costs
and beneﬁts accruing from smoking cessation for a Swedish male
(168,844 males) and female cohort (208,737 females), respec-
tively. The smokers made one quit attempt at the outset of the
simulated period. The model was extended in order to include
indirect effects of smoking cessation on production and con-
sumption due to increased survival. Smoking cessation beneﬁts
were modelled through lower incidence rates of chronic obstruc-
tive pulmonary disorder, coronary heart disease, stroke, and lung
cancer in those who quit. All calculations were performed in
2003 Swedish prices, and transformed into Euros. RESULTS:
Varenicline used for 12 weeks in smoking cessation therapy in
comparison to bupropion has been shown to be a very cost-
effective treatment. A recent study showed that 12 weeks of
additional varenicline treatment in successful quitters will help to
maintain smoking bstinence. Including only health care costs, the
estimated incremental cost per QALY gained was €7066 and
€7108, respectively, for men and women. Taking also indirect
effects on production and consumption of increased survival into
account, the corresponding ﬁgure was about €24,000 for
both men and women. Performed simulations over a 50 year
follow-up period imply that about 19,176 life years are saved.
This corresponds to €8945 QALYs. Sensitivity analyses indicated
that the results are robust. CONCLUSION: An additional
12-weeks course of varenicline provided to successful quitters
produces low incremental cost-utility ratios in the spectrum of
life-saving medical treatments.
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OBJECTIVE: Smoking inﬂuences several acute and chronic dis-
eases within a population which might generate high medical
costs in Korean health care. The aim of this study is to eva-
luate the cost-effectiveness of Varenicline compared with other
smoking cessation interventions: bupropion, NRT(Nicotine
Replacement Therapy), and unaided cessation (willpower) in
smokers who attempt to quit. METHODS: A Markov model was
developed from a societal perspective to estimate long-term
health beneﬁt, smoking cessation cost, and co-morbidity-related
cost. The model simulates cost and outcomes in a hypothetical
cohort of current smokers attempting to quit during their lifetime
with a 5% discount rate. The Markov cycle length is one
year. The model includes six-potential co-morbidities: chronic
obstructive pulmonary disease, ischemic heart disease, stroke,
lung cancer, liver cancer, and gastric cancer. Transition probabili-
ties were obtained from Korean epidemiologic data, whereas
non-smoking rates after treatment, smoking relapses rates, and
relative risk of above diseases were based on the published lit-
erature. Quality-adjusted life years (QALYs) were estimated as
an effectiveness measure. Resource utilization and costs were
calculated with public institutional data. One-way sensitivity
analyses were performed on crucial parameters (discount
rate, time horizons, mortality rate, costs, and utility weight).
RESULTS: As incremental cost-effectiveness ratio (ICER) for
varenicline & bupropion is lower than that of bupropion &
NRT, bupropion is subject to extended dominance. With the
exclusion of bupropion, ICER for vareniciline vs. NRT was
analyzed as US$5096 per quality-adjusted life year (QALY)
during the life time. The results of sensitivity analysis showed
quite stable across most of the included parameters. CONCLU-
SION: Varenicline costs US$5096 more to gain an additional
QALY compared to NRT. Even though the threshold for ICER is
not yet decided in Korea, varenicline can be regarded as a cost-
effective alternative in the long term for the management of
smoking cessation based on the UK & Australian experience.
RESPIRATORY-RELATED DISORDERS—
Patient-Reported Outcomes
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OBJECTIVE: Patterns of medication use and adherence towards
the end of life in chronic obstructive pulmonary disease (COPD)
patients is poorly understood. This study aimed to examine
medication adherence and persistence among COPD patients
during their last year of life. METHODS: From national VA
databases, we identiﬁed newly diagnosed COPD patients between
1999 and 2003 who died during follow-up. We examined use of
inhaled corticosteroids (ICS), long-acting â2 agonists (LABA),
methylxanthines (MTX), and anticholinergics (AC), alone and in
combination. Medication possession ratios (MPR) were com-
pared between regimens by quarterly periods using General Esti-
mating Equations (GEE). Medication persistence, calculated as
the time from index date to an occurrence of at least 30 days
between reﬁlls, was examined in monotherapy users with Kaplan-
Meier survival analysis and extended Cox proportional hazard
models. RESULTS: Among 5913 patients who received medica-
tions and died during follow-up, overall mean (SD)MPRwas 0.44
(0.32) during the last year of life, being highest amongMTX users
(mean MPR = 0.52, SD = 0.32). ICS-only users had lower MPRs
than the AC reference group (â = -0.0311, p = 0.03). A positive
linear trend in MPR was observed across quarterly periods in AC
users (â = 0.014, p < 0.0001), and was highest for MTX users
(â = 0.11, p < 0.0001). MPRs for MTX or multiple medication
users were signiﬁcantly higher than the reference group. Of 3436
on monotherapy only, approximately 40% discontinued medica-
tion within 30 days and 70% discontinued within 90 days. Days
to discontinuation ranged frommean (SD) of 79 (91) for LABA to
126 (129) for MTX. MTX users were less likely to discontinue
(HR = 0.714, p = 0.012) than reference (AC) group. African-
Americans had a higher risk of discontinuation than Caucasians.
CONCLUSION: More severe COPD patients, e.g. methylxan-
thine and multiple medications users, were more adherent and/or
persistent with their regimens. Future research needs to link
compliance to outcomes towards end-of-life.
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